Application effect of Pyrotinib combined with chemotherapy in first-line and above-first-line treatment of human epidermal growth factor recep-tor-2 positive advanced breast cancer
Objective To explore the effect of Pyrotinib combined with chemotherapy in the first-line and above-first-line treatment of human epidermal growth factor receptor-2(HER-2)positive advanced breast cancer(ABC).Methods Clinical data of 106 patients with HER-2 positive ABC admitted to Fujian Medical University Affiliated Sanming First Hospital from March 2020 to May 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group(53 cases)and observation group(53 cases).All patients only had one measurable lesion.The control group was treated with Trastuzumab+Pertuzumab+Capecitabine regimen,and the observation group was treated with Pyrotinib+Capecitabine regimen.Disease control rate(DCR)and objective remission rate(ORR)efficacy,adverse reactions,tumor marker levels(cancer antigen 153[CA153],cancer antigen 199[CA199]and thymidine kinase 1[TK1])and quality of life were compared between the two groups.Results All patients completed at least two cycles of Trastuzumab+Pertuzumab+Capecitabine or Pyrotinib+Capecitabine treatment.There was no significant difference in ORR and DCR between the two groups(P＞0.05).There were no significant differences in the incidence of adverse reactions,including diarrhea,leukopenia,nausea/vomiting,thrombocytopenia and liver function impairment between the two groups(P＞0.05).The left ventricular ejection fraction(LVEF)of the observation group was higher than that of the control group after treatment,and the difference was statistically significant(P＜0.05).The levels of CA153,CA199 and TK1 after treatment were lower than those before treatment,the differences were statistically significant(P＜0.05).There was no significant difference in the levels of CA153,CA199 and TK1 between the two groups after treatment(P＞0.05).The scores of each index of quality of life in the observation group after treatment were higher than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion Pyrotinib combined with chemotherapy in the first-line and above-first-line treatment of HER-2 positive ABC is safe and effective,it can reduce cardiotoxicity and improve patients'quality of life.
Advanced breast cancerHuman epidermal growth factor receptor-2 positivePyrotinibTrastuzumabPatuzumabCapecitabineTumor markersAdverse reactions
万方数据
维普
